Evidence map›Paper›PMID 26717380›Full record

ArticleMedicine2015

Phenotype of NK Cells Determined on the Basis of Selected Immunological Parameters in Children Treated due to Acute Lymphoblastic Leukemia.

Sylwia Koltan, Robert Debski, Andrzej Koltan, Elzbieta Grzesk, Barbara Tejza, Andrzej Eljaszewicz, Lidia Gackowska, Malgorzata Kubicka, Beata Kolodziej, Beata Kurylo-Rafinska and 7 more

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Sylwia KoltanFrom the Departments of Pediatrics, Hematology and Oncology; and Immunology (SK, RD, AK, EG, BT, AE, LG, MK, BK, BK-R, IK, M Wiese, MJ, JM, M Wysocki, JS), Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, and Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland (GG).
Robert Debski
Andrzej Koltan
Elzbieta Grzesk
Barbara Tejza
Andrzej Eljaszewicz
Lidia Gackowska
Malgorzata Kubicka
Beata Kolodziej
Beata Kurylo-Rafinska
Izabela Kubiszewska
Malgorzata Wiese
Milena Januszewska
Jacek Michalkiewicz
Mariusz Wysocki
Jan Styczynski
Grzegorz Grzesk
Creative Commons · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is the most frequent pediatric malignancy. The chemotherapy for ALL is associated with a profound secondary immune deficiency.We evaluated the number and phenotype of natural killer (NK) cells at diagnosis, after the intensive chemotherapy and following the completion of the entire treatment for patients with ALL. The fraction, absolute number, and percentage of NK cells expressing interferon-γ were determined in full blood samples. The fraction of NK cells expressing CD158a, CD158b, perforin, A, B, and K granzymes was examined in isolated NK cells.We have shown that patients assessed at ALL diagnosis showed significantly lower values of the fraction of NK cells and percentage of NK cells with the granzyme A expression. Additionally, the absolute number of NK cells, the expression of CD158a, CD158b, perforin, and granzyme A were significantly lower in patients who completed intensive chemotherapy. Also, there was a significantly higher fraction of NK cells expressing granzyme K in patients who completed the therapy.Abnormalities of NK cells were found at all stages of the treatment; however, the most pronounced changes were found at the end of intensive chemotherapy.

Indexed as

AdolescentAntineoplastic AgentsChildChild, PreschoolFemaleFlow CytometryGranzymesHumansInfantInterferon-gammaKiller Cells, NaturalLymphocyte CountMalePerforinPhenotypePrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsGranzymesInterferon-gammaPerforinReceptors, KIR2DL1Receptors, KIR2DL3

Identifiers

PMID26717380
PMCPMC5291621
OpenAlexW2327386262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.